巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Cyclacel Pharmaceuticals

CYCC
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Cyclacel Pharmaceuticals - 延遲價格・最後更新於 21/01 12:15
最高位
3.150
最低位
3.020
開市價
--
前收市價
3.260
成交量(千)
1.15
成交額(百萬)
0.02
買入
--
賣出
--
每手股數
--
市值(百萬)
31.22
市盈率
--
息率
--
差價
--
52週高低
11.420 - 3.005
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Cyclacel Pharmaceuticals
證券代碼
CYCC.US
所屬板塊
Biotechnology
公司業務
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
發行量
4863984
公司總部
200 Connell Drive, Suite 1500
公司網址
https://www.cyclacel.com
公司電郵
ir@cyclacel.com
公司電話
+1 908 517-7330
暫無內容

關於

Cyclacel Pharmaceuticals(CYCC.US)所屬的行業板塊為Biotechnology。
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.
詳細公司背景可參考: https://www.cyclacel.com